MDA (Medical Devices Agency) reassures industry on fees in MCA (Medicines Control Agency) merger
This article was originally published in Clinica
Executive Summary
UK medical device manufacturers will not be subject to the fees that currently apply to their pharmaceutical counterparts when the two industries' regulatory bodies merge in April 2003 (see Clinica No 1012, pp 3-4). This reassurance was made by David Jefferys, chief executive of the (MDA), at the 10th annual conference on device regulation, hosted by the Association of British Health-Care Industries.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.